Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

CONCLUSIONS: Neither the frequency of AHT nor the increase of BP levels were predictive of efficacy in MBC and mCRC patients treated with bevacizumab-containing chemotherapy.CLINICAL TRIAL REGISTRY: ClinicalTrials.gov Identifier: NCT01733628.PMID:38578537 | DOI:10.1007/s12094-024-03411-w

Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Álvaro Rodríguez-Lescure Javier Gallego Pilar Garcia-Alfonso Bartomeu Massuti Ra úl Márquez Lourdes Calvo Pedro S ánchez-Rovira Antonio Ant ón Jos é Ignacio Chacón Eva Ciruelos Jose Juan Ponce Ana Santaballa Manuel Valladares-Ayerbes Mar ía Rosar Source Type: research